video

Ken Mulvany at SLUSH 2017

AI has the potential to positively and dramatically change our world.  In healthcare, AI advances are being made in diagnosis and better care but is the technology capable of curing disease?

WEB SUMMIT 17: How AI is revolutionising drug discovery

Jackie Hunter, CEO BenevolentBio is giving a talk at Web Summit 2017 on how Artificial Intelligence is revolutionising the methods in drug development.

Using Artificial Intelligence to Accelerate Drug Discovery

Jerome Pesenti CEO, BenevolentTech spoke at Data Driven NYC on October 16th, 2017, about how BenevolentAI is using data to help scientists generate and validate hypotheses.

Using Artificial Intelligence to revolutionise drug discovery and development

Jackie Hunter, CEO BenevolentBio shares her thoughts on how Artificial Intelligence is accelerating drug discovery

CNBC - Healthcare transformation led by AI

BenevolentBio CEO Jackie Hunter speaks about how artificial intelligence has application in health care.

Hot Topics interviews Ken Mulvany, Founder of BenevolentAI

Ken Mulvany, Founder, BenevolentAI, is interviewed by Hot Topics on BenevolentAI as a company and the challenge we are trying to solve. The interview includes how we are helping researchers to access and make sense of the enormous amount of data now available to them.

Looking into the Future of Science Innovation

Jackie Hunter, CEO BenevolentBio gave an interview to Innovation Forum and participated to a panel on how start-up-industry collaborations can be successfully initiated and maintained to drive innovation.

FUTUREPROOF Episode Three, Part One

Matt Gooderick looks at the potential for the use of artificial intelligence in the health sector, including initiatives by IBM Watson, BenevolentAI and Babylon.

BenevolentAI on BBC Business Live

Listen to Kenneth Mulvany, CEO BenevolentAI discussing AI in Medicine at BBC Business Live

Jackie Hunter speaking at The House of Lords

Professor Jackie Hunter, CEO, BenevolentBio, gave evidence at The House of Lords Science and Technology Select Committee

Ken Mulvany talks to CNBC at Goldman Sachs’ Disruptive Technology Symposium

Listen to our founder Ken Mulvany discussing BenevolentAI's work on artificial intelligence applied to drug discovery.

Jérôme Pesenti, CEO BenevolentTech at Project Juno AI Showcase

Jérôme Pesenti introduces BenevolentAI's work on applying artificial intelligence to improve scientific discoveries

Jackie Hunter @ TechCrunch Disrupt London 2016

Ken Mulvany discusses AI, machine learning and the need to build morality into the technology

BenevolentAI – Accelerating Scientific Discovery With AI

BenevolentAI team explains why the use of DGX-1 will help them in their daily work

NVIDIA DGX-1 - Unboxing at BenevolentAI

BenevolentAI London Office

by the team at BenevolentAI